Compare ACADIA Pharmaceuticals Inc. (ACAD) vs Funko Inc (FNKO) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ACADIA Pharmaceuticals Inc. vs Funko Inc — how do they compare? ACADIA Pharmaceuticals Inc. trades at $25.77 (market cap $4.49B), while Funko Inc trades at $5.29 (market cap $301.53M). The key difference: ACADIA Pharmaceuticals Inc. is far larger — about 14.9× Funko Inc's market cap, and Funko Inc is trading nearer its 52-week high, ACADIA Pharmaceuticals Inc. nearer its low. Which is the better fit depends on your goals.
| ACAD | FNKO | |
|---|---|---|
Market Cap | $4.49B | $301.53M |
Sector | Health | Consumer Staples |
52-Week High | $28.06 | $5.88 |
52-Week Low | $20.06 | $2.46 |
Enterprise Value | $3.69B | $546.57M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ACAD trades at $26.20, up 0.89% today, with strong analyst consensus (70% buy ratings) and a $33.67 price target. Recent CHMP recommendation for Daybue in Europe (Business Wire, June 26, 2026) drove positive sentiment. The stock shows bullish technical signals with moving averages supporting upside, though RSI levels indicate overbought conditions. Fundamentally, revenue grew to $1.07B in 2025 with a robust net income margin of 34.3%, though Q1 2026 earnings missed expectations.
Outlook remains positive given commercial execution and pipeline catalysts like remlifanserin data, but risks include earnings volatility and regulatory dependencies. The stock offers growth potential in neuropsychiatry markets, balanced by execution risks in clinical trials and competitive pressures.
FNKO trades at $5.40, down 2.0% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q1 2026 revenue growth to $200.9M, beating EPS estimates, though net income remains negative. Analyst sentiment is mixed with 42.9% buy ratings, while recent news highlights strong product launches and management changes.
The outlook is cautiously optimistic given earnings beats and revenue stabilization, but profitability challenges and negative margins pose risks. Investment opportunity lies in operational turnaround and brand strength, balanced against high debt and competitive pressures in the collectibles market.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About ACADIA Pharmaceuticals Inc.
Acadia Pharmaceuticals is a biotechnology company that develops and commercializes biopharmaceutical products to address central nervous system disorders. The company aims to discover small molecule drugs that address disorders such as Parkinson's, Alzheimer's, and schizophrenia. Acadia also seeks to in-license or acquire complementary products and candidates. The company's patent applications claim proprietary technology, including novel methods of screening and chemical synthetic methods, novel drug targets, and novel compounds identified using its technology.
Read more on ACAD →About Funko Inc
Funko Inc is a US-based pop culture consumer products company. It creates whimsical, fun, and different products which enable the customer to express their affinity for their favorite through movie, TV show, video game, musician or sports team. The company holds licenses and the rights to create tens of thousands of characters including Game of Thrones, Walking Dead, Disney, Marvel, Harry Potter, Fallout, and others. Its products include Pop, Dorbz, Mystery Vinyl, Plush, Action Figures, and Others. The company sells its products through a diverse network of retail customers across multiple retail channels, including specialty retailers, mass-market retailers, and e-commerce sites.
Read more on FNKO →
